We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Stem Cell Therapeutics Corp. announces that it has been granted U.S. Patent 7,704,737 entitled, "Oligodendrocyte Production from Multipotent Neural Stem Cells".

The claims cover the use of granulocyte macrophage colony stimulating factor (GM-CSF) for producing oligodendrocytes from multipotent neural stem cells in culture. This is the second patent to issue in this patent family.

Dr. Alan Moore, President and CEO, commented as follows: "The technology covered by this patent is of potential use as cell transplant therapy for treating demyelinating diseases resulting from oligodendrocyte loss or damage, such as multiple sclerosis and spinal cord injury. This patent expands and adds value to SCT's overall intellectual property portfolio."